Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox

Researchers assigned 440 participants to receive two doses of MVA followed by one dose of the established replicating-vaccinia vaccine ACAM2000 (the MVA group) or to receive one dose of ACAM2000 (the ACAM2000-only group). No safety concerns associated with the MVA vaccine were identified, and immune responses and attenuation of the major cutaneous reaction suggest the MVA vaccine protected against variola infection. 

Emergent BioSolutions awarded contract from HHS to support smallpox preparedness

The US Department of Health and Human Services (HHS) awarded a contract for $535 to Emergent BioSolutions Inc. for Vaccinia Immune Globulin Intravenous (VIGIV) to be used in the Strategic National Stockpile. VIGIV is the only therapeutic licensed by the US Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination.